Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Drug Applications Will Need Pharmacovigilance Plans In 2005

Executive Summary

Pharmaceutical drug marketing applications to the European Medicines Agency will require a pharmacovigilance plan beginning in November 2005

You may also be interested in...



European Pharmacovigilance Draft Guidance May Be Released In Summer

A European Medicines Agency draft guideline on "monitoring and inspection of compliance with pharmacovigilance obligations" is under review in preparation for a public consultation

European Pharmacovigilance Draft Guidance May Be Released In Summer

A European Medicines Agency draft guideline on "monitoring and inspection of compliance with pharmacovigilance obligations" is under review in preparation for a public consultation

FDA’s Risk Management Guidance To Be Harmonized With Europe, Japan

Risk management and risk assessment collaboration between the U.S., Europe and Japan will be one of the topics discussed at the International Conference on Harmonization in Brussels, Belgium from May 9-12

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel